MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Sells $77,019.90 in Stock

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Erez Aminov sold 55,410 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $1.39, for a total transaction of $77,019.90. Following the completion of the sale, the chief executive officer now directly owns 1,105,790 shares in the company, valued at approximately $1,537,048.10. The trade was a 4.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

MIRA Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRA traded down $0.01 during midday trading on Wednesday, hitting $1.27. 162,354 shares of the stock were exchanged, compared to its average volume of 2,151,294. The stock has a market capitalization of $21.03 million, a price-to-earnings ratio of -2.29 and a beta of 3.09. MIRA Pharmaceuticals, Inc. has a 12 month low of $0.51 and a 12 month high of $5.01. The business’s 50-day moving average price is $1.34 and its 200 day moving average price is $1.32.

MIRA Pharmaceuticals (NASDAQ:MIRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. As a group, sell-side analysts expect that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current year.

Wall Street Analysts Forecast Growth

MIRA has been the topic of several recent research reports. RODMAN&RENSHAW upgraded MIRA Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Rodman & Renshaw began coverage on MIRA Pharmaceuticals in a research note on Monday, September 30th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Ascendiant Capital Markets began coverage on MIRA Pharmaceuticals in a report on Monday, August 5th. They set a “buy” rating and a $11.00 price target for the company.

Institutional Investors Weigh In On MIRA Pharmaceuticals

An institutional investor recently raised its position in MIRA Pharmaceuticals stock. Virtu Financial LLC increased its position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 330.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 63,055 shares of the company’s stock after buying an additional 48,397 shares during the quarter. Virtu Financial LLC owned 0.43% of MIRA Pharmaceuticals worth $69,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.